Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock

Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) gene therapy has failed to beat placebo in a phase 2 clinical trial. Functional motor ability scores in the SRP-9001 arm were statistically no better than in the placebo group, almost halving Sarepta’s stock price and raising doubts about a key program.